Open label gabapentin treatment for pain in multiple sclerosis

• Published in: Multiple sclerosis Vol. 3; no. 4; p. 250
• Main Authors: Houtchens, M K, Richert, J R, Sami, A, Rose, J W
• Format: Journal Article
• Language: English
• Published: England 01-08-1997
• Subjects: Acetates - adverse effects; Acetates - therapeutic use; Adult; Aged; Amines; Analgesics - adverse effects; Analgesics - therapeutic use; Anticonvulsants - adverse effects; Anticonvulsants - therapeutic use; Cyclohexanecarboxylic Acids; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Multiple Sclerosis - physiopathology; Pain - classification; Pain - drug therapy; Pain, Intractable - drug therapy
• ISSN: 1352-4585
• DOI: 10.1177/135245859700300407

Pain is a frequent and distressing complaint in patients with multiple sclerosis (MS) and may present a difficult therapeutic problem. Conventional therapy is moderately effective and includes, among others, a variety of anticonvulsant medications. Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy. This study investigates the benefits of open-label treatment with gabapentin for pain control in 25 patients with MS. Excellent to moderate pain relief was obtained in a substantial number of patients. Throbbing pains and needles, and cramping pains responded best, and dull aching pains responded least to the medication. There was no significant change in distribution and type of pain as a result of this treatment. Mild to moderate side effects were observed. Cautious escalation of the dose of gabapentin is advisable in MS patients. Further clinical trials with larger patient groups are recommended.